{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:11:56Z","timestamp":1790914316535,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) acts as an early biomarker of the efficacy of androgen receptor signaling inhibitor (ARSI) therapy. In this study, we aimed to reveal if ctDNA can supplement imaging to better predict metastasis burden and radiographic progression disease (PD) in metastatic castration-resistant prostate cancer (mCRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Targeted next-generation sequencing was performed to assess ctDNA fraction. Radiographic evidence was documented by conventional imaging according to Prostate Cancer Working Group 3 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We prospectively collected plasma samples from 112 mCRPC with bone (n\u2005=\u200577), lymph nodal (n\u2005=\u200531), and visceral (n\u2005=\u20054) metastases. Only bone metastatic patterns were significantly associated with median ctDNA at baseline, during treatment and at PD (P\u2005&amp;lt;.0001). At first radiographic restaging, 24 (31.2%) men with a progressive worsening of bone disease had early ctDNA rise with a % ctDNA variation of 150.6% (interquartile range [IQR]\u2005=\u2005104.9-210.7] compared with 11.1% (IQR\u2005=\u20050-36.6), P\u2005&amp;lt;.0001, in men with no change in bone disease. Univariate analysis showed that early ctDNA rise was significantly associated with progression free\/overall survival (PFS\/OS). In multivariable analysis including ctDNA change from baseline to 3-month treatment, variation of bone metastatic patterns (from oligometastatic to polymetastatic and\/or to widespread disease), presence of visceral metastasis, age, PSA, performance status and prior docetaxel therapy, the transition from low- to high-ctDNA within 3 months of starting ARSI therapy was a significant predictor of OS (HR\u2005=\u20052.50, 90% CI, 1.06-5.88, P\u2005=.035) and persistent high level of ctDNA was a predictor of PFS (HR\u2005=\u20052.53, 95% CI, 1.10-5.81, P\u2005=.028). Metastatic involvement demonstrated that the transition from bone polymetastatic to widespread disease and the presence of visceral metastases were both associated with worse OS (HR\u2005=\u20052.43, 95% CI, 1.10-5.35, P\u2005=.028, and HR\u2005=\u20053.40, 95% CI, 1.50-7.66, P\u2005=.003, respectively). Prior therapy with docetaxel represented an independent predictor of both PFS and OS (HR\u2005=\u20052.47, 95% CI, 1.40-4.35, P\u2005=.002, and HR\u2005=\u20051.78, 95% CI, 1.00-3.15, P\u2005=.049, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early ctDNA variation might reflect changes in metastatic burden and, likely, in bone metastatic patterns on ARSI therapy allowing to track pattern of disease progression and to predict outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf107","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:25:28Z","timestamp":1744701928000},"source":"Crossref","is-referenced-by-count":8,"title":["Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti , 71122 Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rossi","sequence":"additional","affiliation":[{"name":"Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ferroni","sequence":"additional","affiliation":[{"name":"Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bleve","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brighi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-3875","authenticated-orcid":false,"given":"Alessandra","family":"Virga","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Altavilla","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Farolfi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ulivi","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Barone","sequence":"additional","affiliation":[{"name":"Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Matteucci","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Operative Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d 47014 Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025052712343847100_CIT0001","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025052712343847100_CIT0002","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","article-title":"Biological evolution of castration-resistant prostate cancer","volume":"5","author":"Davies","year":"2019","journal-title":"Eur Urol Focus"},{"key":"2025052712343847100_CIT0003","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025052712343847100_CIT0004","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"2025052712343847100_CIT0005","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025052712343847100_CIT0006","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12916-022-02244-0","article-title":"Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel","volume":"20","author":"Gurioli","year":"2022","journal-title":"BMC Med"},{"key":"2025052712343847100_CIT0007","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/1878-0261.13120","article-title":"Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome","volume":"16","author":"Conteduca","year":"2022","journal-title":"Mol Oncol"},{"key":"2025052712343847100_CIT0008","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide","volume":"24","author":"Del Re","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025052712343847100_CIT0009","doi-asserted-by":"publisher","first-page":"e122109","DOI":"10.1172\/jci.insight.122109","article-title":"Tumor fraction in cell-free DNA as a biomarker in prostate cancer","volume":"3","author":"Choudhury","year":"2018","journal-title":"JCI Insight"},{"key":"2025052712343847100_CIT0010","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41416-020-0969-5","article-title":"Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer","volume":"123","author":"Conteduca","year":"2020","journal-title":"Br J Cancer"},{"key":"2025052712343847100_CIT0011","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025052712343847100_CIT0012","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","article-title":"Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial","volume":"32","author":"Jayaram","year":"2021","journal-title":"Ann Oncol"},{"key":"2025052712343847100_CIT0013","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1158\/1078-0432.CCR-21-1625","article-title":"Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition","volume":"27","author":"Annala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025052712343847100_CIT0014","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","article-title":"Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA","volume":"80","author":"Sumanasuriya","year":"2021","journal-title":"Eur Urol"},{"key":"2025052712343847100_CIT0015","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"2018 Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"2025052712343847100_CIT0016","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"key":"2025052712343847100_CIT0017","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"2025052712343847100_CIT0018","doi-asserted-by":"publisher","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025052712343847100_CIT0019","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI130887","article-title":"Genome-wide plasma DNA methylation features of metastatic prostate cancer","volume":"130","author":"Wu","year":"2020","journal-title":"J Clin Invest"},{"key":"2025052712343847100_CIT0020","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"key":"2025052712343847100_CIT0021","doi-asserted-by":"publisher","first-page":"102728","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"2025052712343847100_CIT0022","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer","volume":"25","author":"De Laere","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025052712343847100_CIT0023","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/pros.24331","article-title":"Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer","volume":"82","author":"Antonarakis","year":"2022","journal-title":"Prostate"},{"key":"2025052712343847100_CIT0024","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.13121782","article-title":"Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer\u2013factors affecting diagnostic success","volume":"269","author":"Spritzer","year":"2013","journal-title":"Radiology"},{"key":"2025052712343847100_CIT0025","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/1078-0432.CCR-05-1250","article-title":"Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer-a Cancer and Leukemia Group B study","volume":"11","author":"Ross","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025052712343847100_CIT0026","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cncr.31173","article-title":"Bone biopsy protocol for advanced prostate cancer in the era of precision medicine","volume":"124","author":"Sailer","year":"2018","journal-title":"Cancer"},{"key":"2025052712343847100_CIT0027","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clgc.2016.04.016","article-title":"Castration-resistant prostate cancer tissue acquisition from bone metastases for molecular analyses","volume":"14","author":"Lorente","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"2025052712343847100_CIT0028","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00428-023-03660-0","article-title":"SIUrO best practice recommendations to optimize BRCA 1\/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)","volume":"483","author":"Cimadamore","year":"2023","journal-title":"Virchows Arch"},{"key":"2025052712343847100_CIT0029","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO Guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025052712343847100_CIT0030","doi-asserted-by":"publisher","first-page":"1758835920987654","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2025052712343847100_CIT0031","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"2025052712343847100_CIT0032","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025052712343847100_CIT0033","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025052712343847100_CIT0034","doi-asserted-by":"publisher","first-page":"12436","DOI":"10.3390\/ijms241512436","article-title":"Impact of somatic DNA repair mutations on the clinical outcomes of bone metastases from castration-resistant prostate cancer","volume":"24","author":"Cursano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025052712343847100_CIT0035","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10585-022-10179-2","article-title":"Osteoclasts directly influence castration-resistant prostate cancer cells","volume":"39","author":"Huang","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"2025052712343847100_CIT0036","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-22-2526","article-title":"Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer","volume":"29","author":"Quinn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025052712343847100_CIT0037","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3390\/cancers14092219","article-title":"Baseline plasma tumor DNA (ctDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide","volume":"14","author":"Conteduca","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025052712343847100_CIT0038","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"key":"2025052712343847100_CIT0039","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2217\/fon.15.158","article-title":"Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients","volume":"11","author":"Conteduca","year":"2015","journal-title":"Future Oncol"},{"key":"2025052712343847100_CIT0040","doi-asserted-by":"publisher","first-page":"567809","DOI":"10.3389\/fonc.2020.567809","article-title":"Plasma AR copy number changes and outcome to abiraterone and enzalutamide","volume":"10","author":"Gurioli","year":"2020","journal-title":"Front Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf107\/63208631\/oyaf107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf107\/63208631\/oyaf107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:34:46Z","timestamp":1748349286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf107\/8133685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf107","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf107"}}